Amgen cancer vaccine due for FDA decision by Oct. 27; GAVI pledges top $7.5B;

> After a three-month delay in its FDA review, Amgen ($AMGN) is expecting a regulatory decision on its cancer vaccine, T-Vec, by Oct. 27. Release

> The GAVI Pledging Conference in Berlin saw new pledges totaling $7.54 billion. Report

> GlaxoSmithKline's ($GSK) Ebola vaccine is safe and generates an immune response, researchers have found. Report

> Three different recombinant protective antigen vaccines formulated with Immunovaccine's DepoVax tech protected animals against a lethal anthrax challenge after one vaccination. Release

> The OTC biotech Vaccinogen says it's closed a previously reported deal for $10 million to study its therapeutic cancer vaccine OncoVax. Release

> A unit of China's Hualan Biological has received government approval to run clinical trials of its H7N9 vaccine. Report

> Tau-based vaccines could transform early Alzheimer's disease treatment, according to GlobalData. Release

And Finally... "Customized soap bubbles" could transform vaccine delivery. More



Suggested Articles

AZ's FluMist will be dramatically limited in the U.S. this flu season because of production problems, a spokeswoman said.

As Merck and Pfizer race to market with next-gen vaccines, the companies are fighting in court over a trade secrets lawsuit from Merck.

After working with the government for years to advance a next-gen smallpox vaccine, Bavarian Nordic has finally scored its approval.